TI
RARE icon

Tidal Investments’s Ultragenyx Pharmaceutical RARE Stock Holding History

Tidal Investments’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,563
Closed -$242K – 2775
2026
Q1 		$242K Buy
+11,563
New +$260K ﹤0.01% 2115
2025
Q4 		– Sell
-11,947
Closed -$359K – 2298
2025
Q3 		$359K Sell
11,947
-644
-5% -$19.3K ﹤0.01% 1745
2025
Q2 		$458K Buy
12,591
+564
+5% +$20.3K ﹤0.01% 1459
2025
Q1 		$435K Sell
12,027
-998
-8% -$41.5K ﹤0.01% 1393
2024
Q4 		$548K Sell
13,025
-658
-5% -$32.6K ﹤0.01% 1331
2024
Q3 		$760K Buy
13,683
+7
+0.1% +$357 0.01% 1150
2024
Q2 		$562K Buy
+13,676
New +$584K 0.01% 1240

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Tidal Investments's RARE Position: Q2 2026 in Review

Tidal Investments sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 11,563 shares — an estimated $242K sold.

Tidal Investments first reported a position in RARE in Q2 2024 and held it in 7 quarters. The position peaked at $760K in Q3 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Tidal Investments reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Tidal Investments sold 11,563 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $242K.
  • Tidal Investments first reported a position in Ultragenyx Pharmaceutical in Q2 2024 and held it in 7 quarters.
  • Tidal Investments's Ultragenyx Pharmaceutical position peaked at $760K in Q3 2024.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Tidal Investments's 13F filing for Q2 2026, filed 13 Aug 2026.